In re: Tricida, Inc., Jackson Square Advisors, LLC, in its capacity as the Liquidating Trustee of the Tricida Liquidating Trust v. David Bonita, et al.

CourtUnited States Bankruptcy Court, D. Delaware
DecidedJune 29, 2026
Docket25-52431
StatusUnknown

This text of In re: Tricida, Inc., Jackson Square Advisors, LLC, in its capacity as the Liquidating Trustee of the Tricida Liquidating Trust v. David Bonita, et al. (In re: Tricida, Inc., Jackson Square Advisors, LLC, in its capacity as the Liquidating Trustee of the Tricida Liquidating Trust v. David Bonita, et al.) is published on Counsel Stack Legal Research, covering United States Bankruptcy Court, D. Delaware primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
In re: Tricida, Inc., Jackson Square Advisors, LLC, in its capacity as the Liquidating Trustee of the Tricida Liquidating Trust v. David Bonita, et al., (Del. 2026).

Opinion

IN THE UNITED STATES BANKRUPTCY COURT FOR THE DISTRICT OF DELAWARE In re: Chapter 11

TRICIDA, INC., Case No. 23-10024 (CTG)

Debtor. JACKSON SQUARE ADVISORS, LLC, in its capacity as the Liquidating Adv. Proc. No. 25-52431 (CTG) Trustee of the Tricida Liquidating Trust, Related Docket Nos. 24, 28

Plaintiff,

v.

DAVID BONITA, et al.,

Defendants. MEMORANDUM OPINION The debtor developed a drug that it hoped would be effective in treating kidney disease. The drug, however, failed clinical trials and did not receive FDA approval. Left without a viable business but holding very substantial net operating losses – tax attributes that could potentially have had material value – the debtor began a process of exploring a sale, including one that, it is argued, might have monetized the company’s tax attributes. The efforts to locate a buyer outside of bankruptcy, however, were unsuccessful and the debtor ultimately filed this chapter 11 case. The trustee filed this adversary proceeding alleging that the company lost the value of its tax attributes, before bankruptcy, through a complex set of self-dealing transactions.1 The allegation is that OrbiMed, the company’s largest shareholder, desperately wanted to sell its shares after the failed clinical trials. OrbiMed was apparently concerned, however, that having appointed two directors to the company’s

board, it would have securities law exposure if it sold during a time when the company did not permit its own insiders to trade the company’s shares. Federal securities laws, of course, prohibit the trading of securities on inside information.2 To facilitate compliance with the securities laws, companies create “trading windows” for insiders who are likely to have material nonpublic information. A company’s “trading window” is a scheduled time when employees and executives are allowed to trade the company’s stock. Outside that window, the company

prohibits insiders from trading so that they do not trade while (perhaps inadvertently) holding important confidential information, like unreleased earnings or news of some other significant event that would affect the value of the company’s shares. Such windows typically open after the company has publicly announced its results or other key information, thereby leveling the playing field for all investors.

1 The plaintiff in this action, Jackson Square Advisors in its capacity as the liquidating trustee of the Tricida Liquidating Trust, is referred to as the “trustee.” The defendants are Klaus Veitinger and David Bonita (both of whom were directors appointed by OrbiMed Advisors, LLC, the company’s largest shareholder, which is referred to as “OrbiMed”), Robert Alpern (a director who was not appointed by OrbiMed), Robert McKague, Geoffrey Parker, and Gerrit Klaerner (all officers of the company who allegedly participated in the decision to open the trading window, and who were alleged to have received retention bonuses), and Dawn Otto (formerly Parsell) (an officer who is not alleged to have participated in the decision to open the trading window, but who is alleged to have received a retention bonus). 2 See generally 15 U.S.C. § 78j(b) (Section 10(b) of the Securities Exchange Act of 1934); 17 C.F.R. § 24010.b-5 (Rule 10b-5); Chiarella v. United States, 445 U.S. 222 (1980). The trustee’s theory is that the directors (Bonita, Veitinger, and Alpern, the first two of whom were appointed by OrbiMed), approved retention bonuses for the officers who made the decision whether to open the trading window (McKague,

Parker, and Klaerner). In exchange for those bonuses, it is alleged that the Officers in fact opened the trading window. OrbiMed then sold its shares, which amounted to a change in ownership that under the tax laws destroyed the company’s net operating losses. But despite the complaint’s intonation of a conspiracy, the complaint does not allege that the company had a duty to make decisions about opening or closing the trading window with an eye towards preserving the value of its net operating losses.

Instead, the trustee’s argument is that the company’s insiders in fact had access to material nonpublic information at the time the officers decided to open the trading window, and that opening the window while insiders had material nonpublic information breached the fiduciary duty by permitting what was, in substance, improper insider trading. As the trustee puts it, the directors and officers “broke their promised fidelity to Tricida and breached their fiduciary duties by decimating

the value of Tricida’s [net operating losses], paying themselves millions of dollars in bonuses, and trading on insider (non-public) information.”3 The defendants moved to dismiss the complaint under Rule 12(b)(6), asserting that it failed to state a claim. The Court will grant the motion without prejudice to the trustee’s right to seek leave to amend (or the defendants’ right to oppose it). The

3 D.I. 1 ¶ 4. core problem with the trustee’s various claims is that he acknowledges that the Court can take judicial notice of the fact that the decision to open the trading window was made promptly after the company made a public disclosure, in an 8-K filing with the

SEC, of the fact that the company had begun exploring strategic alternatives. That 8-K, however, is not mentioned in the complaint. Without addressing the substance of those disclosures, the complaint does not plausibly allege that the company in fact opened the trading window while its insiders were still in possession of material inside information. That failure is fatal to the complaint’s core allegation of improper manipulation of that trading window for the benefit of OrbiMed. The complaint’s basic claim for

breach of fiduciary duty against the directors and officers fails for that reason. The claim that the officers breached the duty of care when they opened the trading window fails because there is no allegation that the company had material nonpublic information at the time the officers voted to open the trading window. The Brophy claim, one for trading on material nonpublic information, likewise fails for the same reason. The claim of corporate waste fails to meet the very high bar applicable to

such claims because the trustee acknowledges that the decision to pay retention bonuses to retain the company’s senior leadership as the company encountered financial distress is customary in such circumstances. And in the absence of any affirmative claim of breach, the aiding and abetting claim also fails. Factual and Procedural Background After years of development and operating losses, Tricida learned in October 2022 that its drug to treat kidney disease had failed clinical trials and would not receive FDA approval.4 The company filed a Form 8-K to disclose the failure to the public.5 At this time, the company had accumulated a significant amount, $740 million, of net operating losses.6 Without a viable business, but with the potentially

valuable net operating losses, the company initiated a strategic alternatives process in an attempt to monetize the value held in those tax attributes.7 The fact that the company had begun a strategic alternatives process to maximize value was disclosed in early November 2022.8 Throughout this time, the company’s trading window for insiders remained closed, as it had since 2020, due to the fact that insiders possessed material nonpublic information concerning the development and subsequent failure of the kidney disease drug.9

Free access — add to your briefcase to read the full text and ask questions with AI

Related

TSC Industries, Inc. v. Northway, Inc.
426 U.S. 438 (Supreme Court, 1976)
Chiarella v. United States
445 U.S. 222 (Supreme Court, 1980)
Bell Atlantic Corp. v. Twombly
550 U.S. 544 (Supreme Court, 2007)
Ashcroft v. Iqbal
556 U.S. 662 (Supreme Court, 2009)
United States v. Randall K. Wood
925 F.2d 1580 (Seventh Circuit, 1991)
Fowler v. UPMC SHADYSIDE
578 F.3d 203 (Third Circuit, 2009)
Lewis v. Vogelstein
699 A.2d 327 (Court of Chancery of Delaware, 1997)
Malpiede v. Townson
780 A.2d 1075 (Supreme Court of Delaware, 2001)
In Re Oracle Corp.
867 A.2d 904 (Court of Chancery of Delaware, 2004)
Cargill, Inc. v. JWH Special Circumstance LLC
959 A.2d 1096 (Court of Chancery of Delaware, 2008)
Sinclair Oil Corporation v. Levien
280 A.2d 717 (Supreme Court of Delaware, 1971)
Brehm v. Eisner
746 A.2d 244 (Supreme Court of Delaware, 2000)
Nemec v. Shrader
991 A.2d 1120 (Supreme Court of Delaware, 2010)
Penn Mart Realty Company v. Becker
298 A.2d 349 (Court of Chancery of Delaware, 1972)
Stone v. Ritter
911 A.2d 362 (Supreme Court of Delaware, 2006)
In Re Walt Disney Co. Derivative Litigation
906 A.2d 27 (Supreme Court of Delaware, 2006)

Cite This Page — Counsel Stack

Bluebook (online)
In re: Tricida, Inc., Jackson Square Advisors, LLC, in its capacity as the Liquidating Trustee of the Tricida Liquidating Trust v. David Bonita, et al., Counsel Stack Legal Research, https://law.counselstack.com/opinion/in-re-tricida-inc-jackson-square-advisors-llc-in-its-capacity-as-the-deb-2026.